Anti-tumor activity of fucoidan is mediated by nitric oxide released from macrophages

KAORI TAKEDA1,2*, KOH TOMIMORI1,3*, RYUICHIRO KIMURA1,4*, CHIE ISHIKAWA1,4, TAMARA K. NOWLING5 and NAOKI MORI1

1Department of Microbiology and Oncology, Graduate School of Medicine, University of the Ryukyus, 207 Uehara, Nishihara, Okinawa 903-0215; 2Kanehide Bio Co., Ltd., 5-2-2 Nishizaki-cho, Itoman, Okinawa 901-0305; 3Department of Psychiatry, Naha City Hospital, 2-31-1 Furujima, Naha, Okinawa 902-8511; 4Transdisciplinary Research Organization for Subtropics and Island Studies, 1 Senbaru, Nishihara, Okinawa 903-0213, Japan; 5Department of Medicine, Division of Rheumatology, Medical University of South Carolina, 96 Jonathon Lucas Street, Ste 912 CSB, Charleston, SC 29425, USA

Received June 15, 2011; Accepted July 28, 2011

DOI: 10.3892/ijo.2011.1168

Abstract. Fucoidan, a sulfated polysaccharide, has significant cytotoxic activity against tumor cells; however, the mechanism(s) of this action remains poorly understood. The present study was designed to determine the in vitro and in vivo effects of fucoidan and their molecular mechanisms. Fucoidan from Cladosiphon okamuranus Tokida cultivated in Okinawa, Japan, delayed tumor growth in Sarcoma 180 (S-180)-bearing mice. However, it failed to inhibit S-180 cell growth in vitro. Activated macrophages are known to have anti-tumor effects. Murine RAW264.7 macrophages stimulated with fucoidan exerted cytotoxicity towards S-180 cells in vitro. This cytotoxicity was associated with nitric oxide (NO) production. Both cytotoxic effect and NO production were significantly inhibited by L-NAME, an inhibitor of NO synthase (NOS). Furthermore, activation of nuclear factor-κB was a key step in the transcriptional activation of the inducible NOS gene. Taken together, our results indicate that the anti-tumor activity of fucoidan on S-180 cells is mediated through increased NO production by fucoidan-stimulated macrophages via nuclear factor-κB-dependent signaling pathway.

Introduction

Fucoidan is a complex sulfated polysaccharide found in the cell walls of several edible brown algae, including Fucus vesiculosus. The structure and composition of fucoidan vary among different brown seaweed species, but generally the compound consists primarily of L-fucose and sulfate, along with small quantities of D-galactose, D-mannose, D-xylose and uronic acid (1). Previous studies have shown that fucoidan has significant biological activities, such as anti-bacterial (2), anti-viral (3), anti-coagulant (4), anti-oxidant (5), anti-inflammatory (4,6) and immunomodulatory effects (2,7). Other studies also described anti-carcinogenic properties (8-15). For example, in vitro studies demonstrated that fucoidan can inhibit cell proliferation and induce cell death in numerous cell lines, including human bile duct cancers (8), non-small-cell bronchopulmonary carcinoma (9) and lymphoma (10). It is also reported to inhibit the invasion of HT1080 human fibrosarcoma cells and the angiogenic activity of HeLa human uterine carcinoma cells (11). In vivo studies have also demonstrated that fucoidan is a potent anti-neoplastic compound; and is reported to suppress the growth of Ehrlich ascites carcinoma (12,13), Lewis lung carcinoma and B16 melanoma (14), and also inhibit the metastasis of 13762 MAT rat mammary adenocarcinoma (15).

We have examined the anti-tumor effect of fucoidan, which was purified from Cladosiphon okamuranus Tokida cultivated in Okinawa, Japan. Although fucoidan was effective in inhibiting the in vivo growth of implanted Sarcoma-180 (S-180) cells, it did not inhibit the growth of the same cells in vitro. Following activation by a variety of stimuli, it seems that interferon-γ activates macrophages to induce tumor cytotoxicity (16). The present study was designed to further examine the cytotoxic effect of fucoidan. Specifically, we examined the effects of fucoidan on nitric oxide (NO) production in murine macrophages, and its related cytotoxic effect on S-180 cells in vitro.

Materials and methods

Reagents. The unsalted brown seaweed C. okamuranus Tokida was suspended in water, 0.57% (w/vol) citric acid was added to the solution, and then heated at 90°C for 40 min. The suspension was neutralized with NaOH and cooled at 40°C. It was centrifuged at 3500 x g by decantation centrifugal separator. The supernatant was collected, filtered by Cohlo filter, and concentrated by ultrafiltration (MW cutoff 6000). The extracts were dried by spraydrier. They were composed of carbohydrates (72%), uronic acids (24%) and sulfate (8%). The amount of total carbohydrates was determined by the phenol-H2SO4 method using fucose as...
standard. Uronic acids were determined by the carbazole-H2SO4 method using D-glucuronic acid as the standard. Sulfate contents were measured by ion chromatography. The main carbohydrates were fucose. The content of fucoidan determined by high-performance liquid chromatography was 83% and MW was 21-kDa. Fucoidan was dissolved in phosphate-buffered saline at a concentration of 30 mg/ml. Antibodies to p52 for Western blot analysis and nuclear factor-κB (NF-κB) subunits p65, p50, c-Rel and p52 for super shift assay were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Antibody to actin was purchased and p52 for super shift assay were purchased from Santa Cruz, CA. Fucoidan was administered by oral gavage every day for 21 days.

Analysis of cell cycle. Cell cycle analysis was performed with the Cycletest Plus DNA reagent kit (Becton-Dickinson Immunocytometry Systems). Cell suspensions were analyzed on flow cytometry using Cell-Quest. The population of cells in each cell cycle phase was determined with the ModFit software.

Measurement of NO. Nitrite, the stable end product of NO was measured by a colorimetric assay. Briefly, the medium was removed from individual wells and treated with Griess reagent (1% sulfanilamide and 0.1% naphthylethylene diamine dihydrochloride in 2% H3PO4) for 10 min at room temperature. The optical density of the samples was obtained using an automated microplate reader at 550 nm. A standard curve using a standard solution of NaNO2 in culture medium was employed to calculate the nitrite concentration.

Reverse transcriptase-PCR (RT-PCR). Total cellular RNA from cells was extracted with TRIzol (Invitrogen, Carlsbad, CA) according to the protocol provided by the manufacturer. First-strand cDNA was synthesized from 1 µg total cellular RNA using random primers. The primers used were 5'-TCATTGTACTCTG AGGGCTGTACACA-3' (forward) and 5'-GGCCTTCAACAC CAAGGTGTTCAGCA-3' (reverse) for murine inducible NO synthase (iNOS), and 5'-GTGGGGGCGCCCCAGGACCAAC-3' (forward) and 5'-CTCCTTAATGTGACGACGATTTTC-3' (reverse) for β-actin. The length of RT-PCR was 30 cycles. The PCR products were fractionated on 2% agarose gels and visualized by ethidium bromide staining.

Transfection and luciferase assay. The IkBαΔN dominant-negative mutant is an IkBα deletion mutant lacking the N-terminal 36 amino acids (17). The dominant-negative mutants of IKKα, IKKβ, IKKγ (K44A), IKKγ (1-305) and NF-κB-inducing kinase (NIK), NIK (KK429/430AA) have been described previously (18,19). pGL3 iNOS plasmid was generated by inserting the murine iNOS promoter region (-1588 to +161 bp surrounding the transcription start site) into the pGL3-basic vector (Promega, Madison, WI) (20). Three internal deletion mutants, pGL3 iNOS xB2-, pGL3 iNOS xB1- and pGL3 iNOS xB1/xB2-, were constructed by deletion of two NF-κB sites defined as the xB1 (-85 to -76) and xB2 (-971 to -962). RAW264.7 cells were plated on a plate and transfected with the appropriate reporter and effector plasmids using Lipofectamine.
reagent (Invitrogen) according to the protocol supplied by the manufacturer. After 18-20 h, fucoidan was added and incubated for 6 h. The cells were washed in phosphate buffered saline and lysed in reporter lysis buffer (Promega). Lysates were assayed for reporter gene activity with the dual-luciferase assay system (Promega). Luciferase activities were normalized relative to the Renilla luciferase activity from phRL-TK.

**Electrophoretic mobility shift assay (EMSA).** Nuclear extracts were obtained as described by Antalis and Goldbolt (21) with modifications, and EMSA was performed as described previously (22). Briefly, 5 µg of nuclear extract was incubated with 32P-labeled probes. The DNA-protein complex was separated from the free oligonucleotides on 4% polyacrylamide gel. The probes used were prepared by annealing the sense and antisense synthetic oligonucleotides; a κB1 site from the murine iNOS gene (5'-tcgaCCAACTGGGGACTCTCCCTTTGGGAA-3'), a κB2 site from the murine iNOS gene (5'-tcgaTGCTAGGGGGTTTTCCCTCTCTG-3') and an AP-1 element of the IL-8 gene (5'-gatcGTGA TGACTCAGGTT-3'). The above underlined sequences represent the NF-κB or AP-1 binding site.

**Statistical analysis.** Data are expressed as the mean ± SD. Differences between groups were assessed for statistical significance by the Student's t-test and Mann-Whitney U test as appropriate. P<0.05 denotes the presence of a statistically significant difference.

---

**Results**

**Effects of fucoidan in nude mice inoculated with S-180 cells.** To explore the role of fucoidan on tumor growth in nude mice transplanted with murine S-180, we treated tumor-bearing mice with 100 mg/kg of fucoidan. After 21-day treatment, the mean tumor volume (Fig. 1A, left panel) and weight (Fig. 1A, right panel) were significantly lower than those of vehicle-treated mice. There was no significant difference in body weight gain during the period from day 0 to day 21 between the vehicle and fucoidan-treated groups (data not shown). During this period, mice treated with fucoidan appeared generally healthy. These results suggest that fucoidan has \textit{in vivo} anti-tumor effect.

**Inhibition of S-180 cell growth in vitro in the presence of fucoidan and RAW264.7 cells but not by fucoidan alone.** To study the mechanism of the anti-tumor effect of fucoidan, we determined the effects of fucoidan on cell growth of S-180 cells \textit{in vitro}. Cell growth was assessed by the WST-8 assay. Incubation with fucoidan alone at concentrations up to 1000 µg/ml for 72 h did not affect cell growth (Fig. 1B).

Activation of macrophages by agents such as bacterial lipopolysaccharide (LPS) stimulates their growth inhibitory effects on a wide variety of tumor cells (23). Based on this property, we next investigated the effects of macrophages on S-180 cells. RAW264.7 cells and S-180 cells were incubated together in different chambers separated by a semipermeable membrane.
with or without fucoidan. Fucoidan did not exert any growth inhibitory activity on S-180 cells by itself, similar to the data shown in Fig. 1B, but it inhibited cell growth when cocultured with RAW264.7 cells (Fig. 1C).

S-180 cells were also cultured in the supernatants from RAW264.7 cells that had been stimulated with various concentrations of fucoidan. The supernatants suppressed cell growth of S-180 cells in a fucoidan dose- and time-dependent manner, while fucoidan-containing control medium had no growth inhibitory activity on S-180 cells (Fig. 2A). Thus, the RAW264.7-associated inhibition of S-180 cell growth during in vitro culture seems to depend on crosstalk between the two cell populations.

**Supernatant from fucoidan-stimulated RAW264.7 cells causes cell cycle arrest and apoptosis.** To gain insight into the mechanism of the cell growth inhibitory effects of RAW264.7 supernatants, we used flow cytometry to examine the cellular DNA contents distribution in S-180 cells incubated for 24 h with supernatants from fucoidan-stimulated RAW264.7 cells or with supernatants from unstimulated RAW264.7 cells (control) (Fig. 2B). The supernatant from fucoidan-stimulated RAW264.7 cells increased the population of S-180 cells in the S and G2/M phases, and markedly reduced cells in the G1 phase, relative cells incubated with the control. These results indicate that the supernatant from fucoidan-stimulated RAW264.7 cells induces S and G2/M arrest in S-180 cells. To further characterize the cytotoxicity of fucoidan-stimulated RAW264.7 supernatants against S-180 cells, we next analyzed the proportion of apoptotic cells by the Annexin-V method. In this assay, Annexin-V binds to the cells that express phosphatidylserine on the outer layer of the cell membrane, a characteristic feature of cells entering apoptosis (24). Treatment with supernatant from fucoidan-stimulated RAW264.7 cells increased, in a time-dependent manner, the proportion of cells positive for Annexin-V in S-180 cells, relative to cells treated with the control supernatant (Fig. 2C). These results indicate that, in addition to the induction of cell cycle arrest, the supernatant of fucoidan-stimulated RAW264.7 induces apoptosis of S-180 cells.

**Fucoidan induces NO production and expression of iNOS mRNA and protein in RAW264.7 cells.** Previous studies demonstrated the crucial role of NO in the tumoricidal activity of murine macrophages (25). Therefore, we examined the effects of fucoidan on NO production by RAW264.7 cells and the related anti-tumor effect on S-180 cells in vitro. NO production upon stimulation of RAW264.7 cells was assessed by measuring nitrite in the culture medium. Fucoidan stimulated the production of nitrite from RAW264.7 cells in a dose- and time-dependent manner (Fig. 3A).

NO is synthesized by NOS-catalyzed conversion of L-arginine to L-citrulline. Whereas the activity of neuronal and endothelial NOS is mainly regulated post-translationally by cytoplasmic calcium levels or by phosphorylation by various protein kinases, iNOS is primarily regulated at the transcriptional level (26). To determine whether fucoidan-induced NO production from RAW264.7 cells was catalyzed by iNOS, we measured the iNOS level. When 250 µg/ml fucoidan was added to RAW264.7 cells, iNOS mRNA was detected from 3 h after treatment (Fig. 3B, bottom panels). When RAW264.7 cells were incubated with fucoidan for 6 h, fucoidan induced iNOS
mRNA expression at 15.6 µg/ml (Fig. 3B, top panels). The results also confirmed that 15.6 µg/ml fucoidan significantly increased iNOS protein level in RAW264.7 cells (Fig. 3C). These results suggest that the fucoidan-induced increase in NO production in RAW264.7 cells is mediated by the induction of iNOS expression.

In vitro anti-tumor effect of fucoidan-stimulated RAW264.7 cells on S-180 cells involves NO. To validate the effect of NO on S-180 cells, we added exogenous NO donor, NOR3, to the culture medium of S-180 cells. The concentration of nitrite in the culture medium and relative cell growth of S-180 cells in cocultures of fucoidan-stimulated RAW264.7 cells and S-180 cells in the presence of L-NAME were determined. RAW264.7 cells were cultured with or without fucoidan (250 µg/ml) in the presence of 0, 1, 2.5 or 5 mM L-NAME for 72 h (left panel). The concentration of nitrite in the culture medium was determined. S-180 cells were cultured in the presence or absence of fucoidan (250 µg/ml) and L-NAME (1 mM) together with RAW264.7 cells separated by a semipermeable membrane for 72 h (right panel). The relative cell growth of S-180 was determined by WST-8 assay. Data are mean ± SD of triplicate cultures. *P<0.001, compared with the growth of S-180 cells cocultured with fucoidan-stimulated RAW264.7 cells in the absence of L-NAME.
was determined simultaneously. Increasing amounts of NOR3 produced increasing amounts of nitrite in the culture medium (Fig. 4A, left panel), and there was a close relationship between the concentration of nitrite and the extent of cell growth inhibition in S-180 cells, as demonstrated by WST-8 assay (Fig. 4A, right panel).

To further evaluate the sensitivity of S-180 cells to the effect of NO, RAW264.7 cells were stimulated with fucoidan, and cocultivated with S-180 cells for 72 h in Transwell cultures. As demonstrated above, fucoidan inhibited S-180 cell growth during coculture with RAW264.7 cells (Fig. 4B, right panel). The addition of L-NAME, an inhibitor of NOS, to the medium decreased both the production of NO (Fig. 4B, left panel) and the suppression of S-180 cell growth (Fig. 4B, right panel). Data displayed in the two figures indicate a close relationship between NO production and S-180 cell growth inhibition by fucoidan-stimulated RAW264.7 cells.

NF-κB is necessary for fucoidan inducibility of iNOS promoter.
To assess the effect of fucoidan on iNOS promoter activity, RAW264.7 cells were transfected with a murine iNOS-luciferase promoter/reporter construct and then incubated with various concentrations of fucoidan. The cells were lysed, and luciferase activity was measured. Fucoidan increased the expression of luciferase from the iNOS promoter in a dose-dependent manner (Fig. 5A). Expression of the iNOS gene in macrophages is regulated mainly at the transcriptional level, particularly by NF-κB (27). The murine iNOS promoter contains two putative NF-κB binding sites, one upstream (GGGATTTTCC, -971 to -962 bp, designated NF-κB1) and one downstream (GGGACTCTCC, -85 to -76 bp, designated NF-κB1) (27). To test the relative contribution of the NF-κB binding sites to the fucoidan-mediated activation of iNOS, we introduced a deletion into each or both sites. A single deletion of the κB2 site markedly inhibited the fucoidan-mediated promoter activation, whereas a single deletion of the κB1 site resulted in moderate activation. The combination of double deletions completely abolished the fucoidan-mediated promoter activation (Fig. 5B).

Fucoidan induces binding of NF-κB family proteins to two NF-κB sites.
We next characterized the nuclear proteins in fucoidan-treated RAW264.7 cells that bind to sequences from the iNOS promoter in an NF-κB-dependent manner. EMSA was performed with two probes; miNOS κB1 and κB2, oligonucleotides consisting of the NF-κB1 and NF-κB2 elements. Fucoidan induced, in a time-dependent manner, the appearance of nuclear proteins that bound to both probes in RAW264.7 cells (Fig. 6A). In both probes, the addition of excess of unlabeled κB1 and κB2 oligonucleotides to the binding reaction completely abolished the formation of the inducible DNA-protein complexes (Fig. 6B, lanes 2 and 9). In contrast, the formation of these DNA-protein complexes was not blocked by the addition of excess of unrelated oligonucleotide AP-1 (Fig. 6B, lanes 3 and 10). To identify the NF-κB family members that bind to the NF-κB motifs of the murine iNOS gene promoter, the binding reactions were preincubated with antibodies specific to p50, p65, c-Rel and p52. The anti-p50 antibody induced the supershifted bands and reduced the intensity of complexes κB1 and κB2 (Fig. 6B, lanes 4 and 11). The anti-p50 antibody blocked the formation of complexes κB1 and κB2 (Fig. 6B, lanes 5 and 12). The c-Rel
antibody supershifted complex κB1 (Fig. 6B, lane 13). These results indicate that the complexes κB1 and κB2 correspond to p50/p65/c-Rel and p50/p65, respectively.

**Effects of fucoidan on signal pathway through NF-κB activation in RAW264.7 cells.** We also examined whether fucoidan-mediated upregulation of iNOS gene expression involves signal transduction components in NF-κB activation. Activation of NF-κB requires the phosphorylation of two conserved serine residues of NF-κB inhibitory subunit, IκBα (Ser32 and Ser36) within the N-terminal domain (28). Phosphorylation leads to the ubiquitination and 26S proteasome-mediated degradation of IκBα, thereby releasing NF-κB from the complex and its translocation to the nucleus and activation of various genes (28). To determine the role of IκBα phosphorylation and degradation in fucoidan-induced NF-κB translocation and activation, we investigated whether fucoidan induces phosphorylation and degradation of IκBα. The latter two processes were examined by Western blot analysis using antibodies against phosphorylated and total IκBα, respectively. Treatment of RAW264.7 cells with fucoidan resulted in phosphorylation and degradation of IκBα within 30 min (Fig. 6C). Furthermore, fucoidan increased iNOS protein level in RAW264.7 cells within 6 h.

**NF-κB signal is essential for fucoidan-induced iNOS expression.** To further confirm the involvement of IκBα phosphorylation and degradation, we transfected the cells with transdominant mutant of IκBα in which two critical serine residues required for inducer-mediated phosphorylation were deleted (17). Overexpression of mutant IκBα inhibited the fucoidan-induced iNOS promoter activation (Fig. 6D), suggesting the involvement of IκBα phosphorylation and degradation in fucoidan-induced iNOS expression.

NF-κB signaling occurs either through the classical or alternative pathway (29). In the classical pathway, NF-κB dimers, such as p50/p65, are maintained in the cytoplasm by interaction with IκBα. Whereas the classical NF-κB activation is IKKβ- and IKKγ-dependent and occurs through IκBα phosphorylation and subsequent proteasomal degradation, the alternative pathway depends on activating NIK to stimulate IKKα-induced phosphorylation and proteolytic processing of the p100 precursor protein to p52 (29). Indeed, fucoidan induced phosphorylation of IKKα and IKKβ within 30 min (Fig. 6C). Furthermore, the level of p52 protein increased in fucoidan-treated RAW264.7 cells (Fig. 6C). To address the mechanism of fucoidan-mediated iNOS expression, we investigated the role of NIK and IKK. Cotransfection with the dominant-negative mutant forms of NIK, IKKα, IKKβ and IKKγ inhibited fucoidan-induced iNOS expression (Fig. 6D). Taken together, these findings clearly demonstrate that fucoidan induces iNOS expression via activation of the NF-κB signaling pathway.

Because activation of the iNOS promoter by fucoidan required the activation of NF-κB, we blocked NF-κB activation with Bay 11-7082, an inhibitor of IκBα phosphorylation (30) or LLnL, a proteasome inhibitor (31). Bay 11-7082 inhibited
fucoidan-induced phosphorylation and degradation of IκBα (Fig. 7A, left panels). Furthermore, LLnL also prevented IκBα degradation, but not IκBα phosphorylation (Fig. 7A, right panels). Bay 11-7082 and LLnL markedly inhibited NF-κB DNA binding (Fig. 7B, lanes 5, 6, 11 and 12). In addition, Bay 11-7082 and LLnL decreased fucoidan-induced iNOS promoter
activity (Fig. 7C). Finally, Bay 11-7082 and LLnL resulted in a dose-dependent reduction in fucoidan-induced iNOS mRNA expression and NO production in RAW264.7 cells (Fig. 8).

Discussion

Previous in vitro and in vivo studies have demonstrated the anti-cancer properties of fucoidan, including the suppression of growth (8,9,12,13), metastasis (11,15), angiogenesis (11,14), and the induction of apoptosis (8,10,32) and autophagy (32) in a variety of cancer cells. In the present study, fucoidan was effective in inhibiting the growth of implanted S-180 cells, but this effect was not mirrored in the in vitro studies. One previous report suggested that the anti-tumor activity of fucoidan is related to the enhancement of immune responses (12). Interestingly, fucoidan-induced tumor regression did not require host T-cell participation since S-180 cell tumors in nude mice regressed upon treatment. On the other hand, previous studies postulated that the macrophage-mediated cytotoxicity against some tumor cells was linked to NO (23,25,26). The present results demonstrated that fucoidan alone could not inhibit S-180 cell growth in vitro. However, fucoidan-treated RAW264.7 cells inhibited S-180 cell growth. This anti-tumor activity correlated with NO production in activated RAW264.7 cells, and the addition of L-NAME, an inhibitor of NOS, inhibited, at least in part, the anti-tumor effect of fucoidan-treated RAW264.7 cells. The partial blockade of fucoidan by L-NAME suggests the possible effects of another significant component of the mechanism causing tumor regression. This in context, it should be emphasized that this experimental approach only allows the study of the effects mediated by soluble mediators. Other interactions involving direct contact between S-180 cells and neighboring macrophages will have additional effects on S-180 cells, modulating the proliferation and apoptosis of S-180 cells.

The other part of the present study investigated the molecular mechanism of fucoidan-induced NO production. The murine iNOS gene promoter contains several homologous consensus sequences for binding the transcription factors such as NF-κB, AP-1 and Stat1 (33). The results highlighted the importance of two NF-κB sites in the iNOS promoter, termed NF-κB1 and NF-κB2, to confer the effects of fucoidan on macrophages. Nuclear protein complexes that bind specifically to NF-κB, AP-1 and c-Rel and p50/p65, respectively. In contrast, NF-κB2, but not NF-κB1, is reported to confer induction by bacterial LPS (27). Fucoidan and LPS are well-defined ligands of the class A scavenger receptor and toll-like receptor 4, respectively (34,35). These results indicate that the mechanism involved in the induction of iNOS expression by macrophage scavenger receptor is likely to be distinct from the mechanism involved in the induction of iNOS by toll-like receptor.

Bay 11-7082 and LLnL are relatively specific inhibitors of NF-κB activation (30,31). Both agents blocked the production of nitrite, the expression of iNOS mRNA, the promoter activity of iNOS and the binding of NF-κB to NF-κB1 and κB2 sites, indicating the likely involvement of NF-κB in the induction not just of iNOS-driven reporter constructs but of the iNOS gene itself in fucoidan-treated macrophages. Two previous studies reported that the interaction of macrophages with fucoidan enhances the production of NO (36,37). However, neither study tested the effect of fucoidan on the binding of NF-κB proteins to the murine iNOS promoter. We found for the first time that the iNOS promoter activation induced by fucoidan was almost eliminated by the deletion of both NF-κB binding sites, even when the AP-1 sites were all conserved. Although the role of AP-1 in the fucoidan-induced NO production has been reported (36), the contribution of AP-1 site is not reasonable for the above result.

We confirmed the important role of NF-κB by showing that overexpression of dominant negative NIK, IKKs and IκBα, potent inhibitors of NF-κB activation, inhibited fucoidan-induced activation of iNOS promoter. Furthermore, fucoidan induced p100 processing into p52 subunit, although supershift experiments did not demonstrate the involvement of p52 in NF-κB-DNA binding complexes in fucoidan-treated RAW264.7 cells. Further studies are needed to explore the role of NIK-dependent alternative NF-κB pathways in fucoidan-induced iNOS expression in macrophages.

Taken together, our data suggest that the regression of murine S-180 tumor by fucoidan involves NO-mediated growth inhibition by activated macrophages, and that fucoidan is a potentially useful anti-tumor agent for some cancers in humans.

Acknowledgements

We acknowledge Drs Dean W. Ballard, Romas Gielezunius and Kuan-Teh Jeang for providing the expression vectors for IκBα-dominant-negative mutant; for NIK, IKKα and IKKβ-dominant-negative mutants; and for IκKγ-dominant negative mutant.

References


